Among patients with AML, the type of anthracycline received, and whether some patients undergoing stem cell transplantation have an HLA-identical donor, may not affect long-term outcomes.
The most frequently observed adverse events among patients treated with sorafenib were cytopenias and skin rashes.
There is warranted excitement for AG-221, a drug recently granted fast track designation by the FDA for acute myelogenous leukemia (AML).
The FDA has granted Fast Track designation to AG-221, a first-in-classinhibitor, to treat AML.
Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.
Results from a new study could benefit some children with high-risk AML. A therapeutic regimen that combined the GO with conventional three-drug chemotherapy was associated with improved survival in children with AML who underwent bone marrow transplantation.
At least one nonsynonymous mutation in a gene relevant for pathogenesis seen in nearly all cases
Assessment of minimal residual disease provides prognostic information for children with AML.
Relapse of acute myeloid leukemia (AML) is associated with acquisition of new mutations and clonal evolution.
